Evidence map›Paper›PMID 41955512›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Causal Prediction of TP53 Variant Pathogenicity Using a Perturbation-Informed Protein Language Model.

Huiying Chen, Yang Zhao, Boqiang Hu, Wuke Wang, Minfang Song, Annabeth Xinyu Zhao, Xiangyang Li, Gefei Wang, Yanfen Wang, Weiyan Zheng and 6 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Huiying ChenThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yang ZhaoThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Boqiang HuThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wuke WangThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Minfang SongResearch Center for Life Sciences Computing, Zhejiang Lab, Hangzhou, Zhejiang, China.
Annabeth Xinyu ZhaoCollege of Science & Medicine, The Australian National University, Canberra, Australia.
Xiangyang LiThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Gefei WangThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yanfen WangThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Weiyan ZhengBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xinpeng ZhangNebraska Food for Health Center, Department of Food Science and Technology, University of Nebraska, Lincoln, Nebraska, USA.
Xia LinThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yanbin YinNebraska Food for Health Center, Department of Food Science and Technology, University of Nebraska, Lincoln, Nebraska, USA.
Xingxu HuangThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0001-8934-1247
Jinfang ZhengResearch Center for Life Sciences Computing, Zhejiang Lab, Hangzhou, Zhejiang, China.
Tingbo LiangThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

Jiangsu Basic Research Center for Synthetic Biology Grant BK20233003Key Research Program of Chinese Academy of Sciences ZDBS-ZRKJZ-TLC008National Key R&D Program of China 2024YFA1306400National Natural Science Foundation of China 82450113R&D Program of Zhejiang 2024SSYS0007
6 · The paper itself

Abstract

Accurate prediction of variant functional impact is crucial for understanding human diseases, particularly for cancer-related genes such as TP53. Advances in high-throughput mutational assays have enhanced variant effect prediction (VEP), but missense classification remains challenging due to the limitations of broad, non-gene-specific models. Here we present CaVepP53, a TP53-specific predictor fine-tuned on perturbation-based experimental variants. The model not only classifies mutations but also quantifies their pathogenicity by calculating Euclidean distances between the wild-type and mutant embeddings and deriving confidence scores through logistic transformation. Benchmarking demonstrates that CaVepP53 significantly outperforms general-purpose models, such as AlphaMissense (AM) and PrimateAI-3D, achieving higher accuracy, precision, and F1-score in predicting pathogenic mutations. Competitive growth assay validation of 22 mutations further confirms CaVepP53's robustness, including 7 functional novel variants absent in the ClinVar database. Thus, by integrating protein language models with experimentally validated functional data, our approach enables accurate, interpretable VEP for TP53, overcoming limitations of predictors trained solely on evolutionary or clinical associations. We further extended this framework to five additional cancer-related genes (VHL, ATM, BRCA1, RAD51C, and BAP1), establishing a generalizable framework for gene-specific VEP with potential applications in precision medicine.

Indexed as

Computational BiologyMutationNeoplasmsTumor Suppressor Protein p53HumansPrediction AlgorithmsTP53 protein, humanTumor Suppressor Protein p53causalpathogenic mutationsperturbationprotein language modelsTP53variant effect prediction

Identifiers

PMID41955512
PMCPMC13285122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.